While NewAmsterdam Pharma Company NV has underperformed by -1.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NAMS rose by 111.36%, with highs and lows ranging from $26.35 to $8.90, whereas the simple moving average jumped by 6.90% in the last 200 days.
On May 15, 2024, TD Cowen started tracking NewAmsterdam Pharma Company NV (NASDAQ: NAMS) recommending Buy. A report published by Scotiabank on March 14, 2024, Initiated its previous ‘Sector Outperform’ rating for NAMS. Guggenheim also rated NAMS shares as ‘Buy’, setting a target price of $30 on the company’s shares in an initiating report dated January 18, 2024. Piper Sandler Initiated an Overweight rating on January 16, 2024, and assigned a price target of $37. RBC Capital Mkts initiated its ‘Outperform’ rating for NAMS, as published in its report on October 30, 2023.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of NewAmsterdam Pharma Company NV (NAMS)
One of the most important indicators of NewAmsterdam Pharma Company NV’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 10.61, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and NAMS is recording 401.89K average volume. On a monthly basis, the volatility of the stock is set at 6.92%, whereas on a weekly basis, it is put at 8.67%, with a loss of -11.99% over the past seven days. Furthermore, long-term investors anticipate a median target price of $37.38, showing growth from the present price of $20.84, which can serve as yet another indication of whether NAMS is worth investing in or should be passed over.
How Do You Analyze NewAmsterdam Pharma Company NV Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 53.55%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 40.61% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NAMS shares are owned by institutional investors to the tune of 40.61% at present.
